"The U.S. Food and Drug Administration today notified Ranbaxy Laboratories, Ltd., that it is prohibited from manufacturing and distributing active pharmaceutical ingredients (APIs) from its facility in Toansa, India, for FDA-regulated drug product"...
Central Diabetes Insipidus: DDAVP (desmopressin acetate tablets) Tablets are indicated as antidiuretic replacement therapy in the management of central diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. DDAVP (desmopressin acetate tablets) is ineffective for the treatment of nephrogenic diabetes insipidus.
Patients were selected for therapy based on the diagnosis by means of the water deprivation test, the hypertonic saline infusion test, and/or response to antidiuretic hormone. Continued response to DDAVP (desmopressin acetate tablets) can be monitored by measuring urine volume and osmolality.
Primary Nocturnal Enuresis: DDAVP (desmopressin acetate tablets) Tablets are indicated for the management of primary nocturnal enuresis. DDAVP (desmopressin acetate tablets) may be used alone or as an adjunct to behavioral conditioning or other non-pharmacologic intervention.
DOSAGE AND ADMINISTRATION
Central Diabetes Insipidus: The dosage of DDAVP (desmopressin acetate tablets) Tablets must be determined for each individual patient and adjusted according to the diurnal pattern of response. Response should be estimated by two parameters: adequate duration of sleep and adequate, not excessive, water turnover. Patients previously on intranasal DDAVP (desmopressin acetate tablets) therapy should begin tablet therapy twelve hours after the last intranasal dose. During the initial dose titration period, patients should be observed closely and appropriate safety parameters measured to assure adequate response. Patients should be monitored at regular intervals during the course of DDAVP (desmopressin acetate tablets) Tablet therapy to assure adequate antidiuretic response. Modifications in dosage regimen should be implemented as necessary to assure adequate water turnover. Fluid restriction should be observed. (See WARNINGS, PRECAUTIONS, Pediatric Use and Geriatric Use.)
Adults and Children: It is recommended that patients be started on doses of 0.05 mg (1/2 of the 0.1 mg tablet) two times a day and individually adjusted to their optimum therapeutic dose. Most patients in clinical trials found that the optimal dosage range is 0.1 mg to 0.8 mg daily, administered in divided doses. Each dose should be separately adjusted for an adequate diurnal rhythm of water turnover. Total daily dosage should be increased or decreased in the range of 0.1 mg to 1.2 mg divided into two or three daily doses as needed to obtain adequate antidiuresis. See Pediatric Use subsection for special considerations when administering desmopressin acetate to pediatric diabetes insipidus patients.
Geriatric Use: This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. (See CLINICAL PHARMACOLOGY, Human Pharmacokinetics, CONTRAINDICATIONS, and PRECAUTIONS, Geriatric Use.)
Primary Nocturnal Enuresis: The dosage of DDAVP (desmopressin acetate tablets) Tablets must be determined for each individual patient and adjusted according to response. Patients previously on intranasal DDAVP (desmopressin acetate tablets) therapy can begin tablet therapy the night following (24 hours after) the last intranasal dose. The recommended initial dose for patients age 6 years and older is 0.2 mg at bedtime. The dose may be titrated up to 0.6 mg to achieve the desired response. Fluid restriction should be observed, and fluid intake should be limited to a minimum from 1 hour before desmopressin administration, until the next morning, or at least 8 hours after administration. (See WARNINGS, PRECAUTIONS, Pediatric Use and Geriatric Use.)
|0.1 mg||Bottle of 100||0016-00||White|
|0.2 mg||Bottle of 100||0026-00||White|
Store at Controlled Room Temperature 20 to 25°C (68 to 77°F) [see USP]. Avoid exposure to excessive heat or light.
This product should be dispensed in a container with a child-resistant cap.
Keep out of the reach of children.
Manufactured for: sanofi-aventis U.S. LLC, Bridgewater, NJ 08807 USA. Rev. July 2007. FDA Rev date: 10/26/2007
Last reviewed on RxList: 2/18/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional DDAVP Information
DDAVP - User Reviews
DDAVP User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.